Overview of Paroxysmal Nocturnal Hemoglobinuria: Pathophysiology of the Complement Pathway and Clinical and Economic Burden

Add-on activity

This activity includes a Powered by Patients™ interview.

Program Description

Paroxysmal nocturnal hemoglobinuria (PNH) is a chronic, rare blood disorder in which a mutation in the X-linked PIGA gene leads to the early hemolysis of red blood cells. Consequences of hemolysis include thrombosis and organ damage, which contribute to the morbidity and mortality associated with PNH. In this first webinar in a 3-part series, pharmacists will become familiar with PNH pathophysiology and the role of the complement system in PNH pathogenesis. In addition, variability in patient presentation, diagnostic criteria, and impact on quality of life will be reviewed. A Powered by Patients™ interview will be included in the presentation to highlight the symptoms, diagnosis, and impact of PNH.

Target audience: Health-system and specialty pharmacists

Type of activity: Application
Release date: June 4, 2024
Expiration date: June 4, 2025

Time to complete activity: 1.0 hour

Learner level: Foundational, Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the clinical and economic impact of paroxysmal nocturnal hemoglobinuria (PNH) on patient morbidity, mortality, and overall disease progression
• Illustrate the complement pathway as it relates to target areas for the treatment of PNH
• Identify goals of therapy and the pertinent laboratory indicators, including the emerging landscape of biomarkers, to inform treatment decisions and enhance long-term patient outcomes

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-24-167-H01-P. The activity is available for CE credit through June 4, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Satheesh Chonat, MD, has the following financial relationships with commercial interests to disclose:

Grant/Research Support: Alexion, GBT/Pfizer, Novartis

Consultant: Agios, Alexion, Amgen, Novartis, Roche/Genentech

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Adam C. Welch, PharmD, MBA, FAPhA; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms